The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2020 | CD3 x CD33 bispecific antibodies redirect donor T-cells against HLA loss
Pier Edoardo Rovatti, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, outlines the ability of anti CD3 x CD33 bispecific antibodies to redirect donor T-cells against HLA loss in leukemia relapses. Dr Rovatti discusses how anti-CD3 x CD33 bispecific antibodies can effectively redirect donor T-cells against HLA loss leukemia variants which is results in their rapid killing. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
